Member Info for TroytoTiber

With the appointment of Mr. Sushil Kumar Roongta, ex executive chairman of SAIL, as a non executive director of Great Eastern Energy i am hopeful that the gas being held back for SAIL whilst they sort out operational issues will be negotiated to be able to be sold in the open market. This will free up another 4 - 5 mcf/d to be sold (currently being flared i think) which would add a 50% uplift to last reported sales gas volume figure for GEEC. My guess is that if pricing holds up and we get this news then the shares are above 100p again.

assuming 100% market share to Genedrive that is. Maybe only 50% share is realistic though.

it looks as if there are around 3m people in the US who have Hep c and are undiagnosed. Given that the disease can remain undiagnosed in people for many years before chronic hep c is diagnosed i think there is a strong case for annual testing of large numbers of the high risk groups of people, especially as the costs of treating chronic hep c sufferers is quite large. so we could maybe assume that in time there might be somewhere in the order of 50m annual hep c tests globally. Assuming 50p per test to Genedrive that could be up to £25m in annual revenue and given the very high operational gearing, this could be valued at c3 to 4x revenues. So best case, on just hep c alone we could be looking at a valuation of £100m in the next few years. Bung in TB, biohazard testing, and some other possible developments and it could be £250m, or 30x times the current share price. I feel better all ready!

824,477 shares traded in one trade. £3m+ order and almost certainly a buy. Followed by another 57,000 share order. That's a statement of intent!!

Wouldn't disagree with that ctw on the re-rate. I'm disappointed though with the situation in India. They have had so long to sort out technical issues regarding the device and the assays that it does call into question the competency of this lot (and the previous lot). Any idea how much the Hep C opportunity is worth?

in the interim results? Clearly full commercial progress with TB tests in India would be very well received, but i am assuming that that would have been made public had it occurred already. so assuming that it hasn't, what constitutes a good update this time around?

of 3 seems too low to me. Even with a lower price assumption for gas pricing in future years, i could see this trading on 10x and 2 to 3 times upside with production and sales volume increases forecast for the next few years.

https://www.iea.org/publications/freepublications/publication/IndiaEnergyOutlook_WEO2015.pdf iea provides a useful backdrop to the outlook for indian gas demand. Near term outlook for gas pricing looks to be strong as higher prices are needed to incentivise new gas resources to be brought to market. GEEC currently achieves around $10/btu. iea estimate that national gas prices tend upwards to $9/btu by 2040. GEEC has c50mmcfd under MOU which we have to assume is around the $10/btu level, so they are clearly able to achieve a higher price than the national average. Landed LNG costs are around $8/btu so with some additional overland transport costs, it does not look like LNG is going to disrupt the price realised by GEEC to any great degree. However, its probably prudent to assume a lower gas price going forward especially if the rupee continues to weaken against the US$. This is the key forecast risk to me as the field reserves and production profiles have been largely derisked now.

GAIL to deliver project to link national pipeline to Durgapur where GEEC dedicated pipeline ends. This national pipeline will therefore connect GEEC to Kolkata and millions of residential gas consumers as well as hundreds of potential industrial customers. Pipeline to be delivered by Dec 2018.

exposure to rapidly increasing Indian gas demand. Largely de-risked coal bed methane play with owned and operational pipeline linking to significant local industrial gas demand. Plans for national pipeline to link companies gas to massive new centre of demand in Kolkata. Not overly indebted, but needs more clarity on production profile and (in the short term at least) clarity on large industrial customer agreements with SAIL and one new large unknown potential buyer. Half of the exploration block planned wells are fracced and drilled out. These existing wells are being worked over though to optimise production, which links back to point on lack of total visibility on production profiles. Feels like investors are being paid to take the risk on this one, but would be good to get views if there is anyone who has read this and prepared to have a look at this one. Very limited liquidity and of course all the caveats that go with a small cap, emerging market resource play, so DYOR is critical.

SYMPHONY ENVIRONMENTAL TECHNOLOGY (SYM.L) 24/01/2017 SHARE PRICE 3.85p 52 WEEK LOW 3.8p MARKET CAP £6.1m 52 WEEK HIGH 6.25p Symphony has developed and is selling a range of additives that help control the life of plastic MAJOR SHAREHOLDERS 1) Somerston – 18.2% 2) M Laurier – 15.3% 3) S Robinson – 5.2% NAV 0.55p NET DEBT £0.1m With global plastics consumption continuing to grow, a company that aims to make plastics smarter should have a strong role to play. Symphony has developed and is selling a range of additives that help control the life of plastic with huge environmental possibilities while newer product areas, focused on protection, are emerging out of an investment phase. With high gross margin potential, the benefit from operational gearing will have a positive impact on forecasts. An early stage company with exciting potential ahead. Technical trials and consumer listings should provide positive newsflow. KEY OPPORTUNITIES • Making Plastics Smarter through specialist masterbatch development and supply • Its controlled life products (d2w) generate revenue with established global distribution • New “designed to protect” offering (d2p) exiting investment phase so has… • …scope to leverage its strong distribution network and d2p potential • Use of 3rd party manufacturing provides cost base flexibility • Plastics is multi-$bn industry and growing – enhancing growth opportunities • …increases need to control degradation and hygiene factors INVESTMENT CASE Symphony Environmental is a specialist plastic masterbatch developer and supplier. This means it has a product suite that helps makes plastics smarter. Global plastics is a multi-$bn market, with c350m tons of polymer produced annually, and estimated to be growing at 3-5%. While the company is at an early stage of its development it already delivers masterbatch, an additive to the manufacturing process, that helps control the degradation of product (d2w). A newer product area is focused on protection and hygiene (d2p – “designed to protect”) is coming to the end of an investment phase. The group has 3rd party manufacturing arrangements in place which along with its global distribution network gives it a genuine international presence. This means that the structure has been established, it has the products and now needs to develop the routes to market. Operational gearing is high which should provide healthy upside to earnings forecasts. FINANCIALS AND VALUATION Current revenue largely consists of its d2w product and we believe that legislation, particularly in emerging markets, will be a positive driver to this revenue stream. We also see the group as operationally geared so bigger contract wins should drop through to profit. With a c50% gross margin the potential for an acceleration in forecasts. Conversion of its c

This looks like a good RNS. With the recent news on product investment and consumer interest across d2w and d2p, along with this upward revision to revenues and profits, 2017 could be a good year for share price momentum. Critical for this stock is upward revenue revision momentum, and whilst not getting carried away this could be the first of many.